| Literature DB >> 28416603 |
Anton W Langerak1, Monika Brüggemann2, Frédéric Davi3, Nikos Darzentas4, Jacques J M van Dongen1, David Gonzalez5, Gianni Cazzaniga6, Véronique Giudicelli7, Marie-Paule Lefranc7, Mathieu Giraud8, Elizabeth A Macintyre9, Michael Hummel10, Christiane Pott2, Patricia J T A Groenen11, Kostas Stamatopoulos12.
Abstract
Analysis and interpretation of Ig and TCR gene rearrangements in the conventional, low-throughput way have their limitations in terms of resolution, coverage, and biases. With the advent of high-throughput, next-generation sequencing (NGS) technologies, a deeper analysis of Ig and/or TCR (IG/TR) gene rearrangements is now within reach, which impacts on all main applications of IG/TR immunogenetic analysis. To bridge the generation gap from low- to high-throughput analysis, the EuroClonality-NGS Consortium has been formed, with the main objectives to develop, standardize, and validate the entire workflow of IG/TR NGS assays for 1) clonality assessment, 2) minimal residual disease detection, and 3) repertoire analysis. This concerns the preanalytical (sample preparation, target choice), analytical (amplification, NGS), and postanalytical (immunoinformatics) phases. Here we critically discuss pitfalls and challenges of IG/TR NGS methodology and its applications in hemato-oncology and immunology.Entities:
Mesh：
Year: 2017 PMID： 28416603 DOI： 10.4049/jimmunol.1602050
Source DB: PubMed Journal: J Immunol ISSN： 0022-1767 Impact factor: 5.422